Core Points - The Shanghai Composite Index closed at 3884.93 points, below the five-day moving average, with a slight decline of 0.11% [1] - The total trading volume of A-shares reached 1,198.5 billion yuan, with 698 A-shares breaking through the five-day moving average [1] Summary by Category Stock Performance - The stocks with the largest deviation from the five-day moving average include Hongxi Technology (15.93%), Huanle Home (12.29%), and Guanzhong Ecology (9.20%) [1] - Notable stocks that just crossed the five-day moving average include Diya Co., Times Wan Heng, and Ketaobiotech, with smaller deviation rates [1] Individual Stock Data - Hongxi Technology: Today's increase of 23.82%, turnover rate of 4.88%, five-day moving average of 30.94 yuan, latest price at 35.87 yuan, deviation rate of 15.93% [1] - Huanle Home: Today's increase of 19.98%, turnover rate of 5.09%, five-day moving average of 24.70 yuan, latest price at 27.74 yuan, deviation rate of 12.29% [1] - Guanzhong Ecology: Today's increase of 15.00%, turnover rate of 16.62%, five-day moving average of 19.80 yuan, latest price at 21.62 yuan, deviation rate of 9.20% [1] - Other notable stocks include Gudewei (11.07%), Qishi Dairy (10.97%), and Fushun Special Steel (10.00%) with respective deviation rates [1]

（文章来源：证券日报） 证券日报网讯 12月12日晚间，科拓生物发布公告称，公司董事兼副总经理乔向前于2025年11月12日至 12月11日通过集中竞价减持2，634，100股，占总股本的0.9997%。本次减持计划已实施完毕。 ...

证券代码：300858 证券简称：科拓生物 公告编号：2025-047 北京科拓恒通生物技术股份有限公司 关于董事兼高级管理人员股份减持计划实施完毕的公告 公司董事兼高级管理人员乔向前保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于2025年9月5 日披露了《关于持股5%以上股东、特定股东以及董事兼高级管理人员减持股份 预披露公告》（公告编号：2025-038）。股东乔向前计划在减持公告披露之日起 15个交易日后的3个月内以集中竞价、大宗交易的方式拟减持公司股份数量不超 过2,635,000股，即不超过公司股份总数的1.0000%。 公司于近日收到董事兼副总经理乔向前出具的《关于股份减持计划实施完毕 的告知函》，截至2025年12月11日，上述减持计划已实施完毕，现将相关情况公 告如下： 一、股东减持情况 （一）股东减持股份情况 | 股东名称 | 减持方式 | | 减持期间 | | | 减持均价 | 减持股数 | 减持比例 | | --- | --- | --- | --- | --- | --- | --- | --- ...

Group 1: Technology Breakthroughs in Inner Mongolia - The "Technology Breakthrough" initiative during the 14th Five-Year Plan aims to leverage Inner Mongolia's unique resources such as wind, solar, rare earths, and dairy to foster high-quality industrial development [1] - Inner Mongolia's new energy industry is experiencing rapid growth, with installed capacity exceeding 143 million kilowatts by May 2025, accounting for 52% of the region's total power generation capacity [3] - The establishment of the "Kubuqi New Energy Base" will enable the transmission of approximately 36 billion kilowatt-hours of electricity annually to the Beijing-Tianjin-Hebei region, significantly reducing coal consumption and carbon emissions [3] Group 2: Rare Earth Industry Developments - Inner Mongolia is focusing on developing its rare earth industry, particularly in Baotou, where innovative technologies are being applied to replace heavy rare earth elements while maintaining product performance [4] - Baotou's production capacity is set to reach 40,000 tons, positioning it as the world's largest high-performance neodymium-iron-boron production base [5] - The region aims for a rare earth industry output value of 130 billion yuan, driven by technological innovation and market-oriented mechanisms [5] Group 3: Dairy Industry Innovations - The establishment of the largest probiotic smart factory in Asia by Inner Mongolia Ketaobiotech aims to achieve technological breakthroughs in the dairy sector [6] - The National Grass Technology Innovation Center is developing advanced grass varieties and technologies to support dairy farming, ensuring a stable supply of quality feed [7] - Inner Mongolia has created a complete ecological system for the dairy industry, integrating all elements from grass cultivation to milk production and processing [7] Group 4: Hydrogen and Energy Innovations - The world's first hydrogen-ammonia dual-fuel gas turbine has been successfully assembled in Inner Mongolia, marking a significant advancement in zero-carbon energy technology [8] - This gas turbine can operate on hydrogen, ammonia, and natural gas, facilitating a complete energy production and consumption cycle [9] - The introduction of a new energy mining truck project combines photovoltaic power generation, intelligent storage, and super-fast charging technology, enhancing the efficiency of heavy-duty transportation [10]

Core Viewpoint - The company, Keta Bio (300858), has clarified its policy regarding the disclosure of shareholder numbers, stating that it will provide this information only in periodic reports, while inquiries for other months require written proof of shareholding [1] Group 1 - The company is obligated to disclose the number of shareholders in its periodic reports as per relevant disclosure regulations [1] - For inquiries regarding shareholder numbers in other months, shareholders must provide written proof of their share type and quantity [1] - The company will verify shareholder identity before providing the requested information [1]

公司于近日收到持股5%以上股东宁波顺懿出具的《关于减持股份触及1%整 数倍的告知函》，现将相关情况公告如下： | 1.基本情况 | | | | | --- | --- | --- | --- | | 信息披露义务人 | 宁波顺懿创业投资合伙企业（有限合伙） | | | | 住所 | 浙江省宁波象保合作区航天大道 99 号 13 幢 1001B 室 | | | | 权益变动时间 | 年 月 日 2025 11 24 | | | | 权益变动过程 | 宁波顺懿于2025年11月24日通过集中竞价方式减持公司股份211,500股，占 公司总股本的0.0803%，其持有公司的股份由23,925,966股变更为23,714,466 股，占公司总股本比例由9.0802%降低至9.0000%，权益变动比例触及1%的 整数倍。本次权益变动不会导致公司控股股东及实际控制人发生变化，不会 | | | | 股票简称 | 对公司治理结构和持续经营产生影响。 科拓生物 股票代码 300858 | | | | 变动方向 上升□ | 下降 一致行动人 有□ 无 | | | | 是否为第一大股东或实际控制人 | | 是□ | 否 | ...

Group 1 - The company, Keta Bio (300858), operates in the food manufacturing industry, focusing on the research, production, and sales of edible probiotics, animal and plant micro-ecological preparations, and compound food additives [1] - The company has also made early investments in the pharmaceutical sector, collaborating with Shenzhen Unknown Jun Biotechnology Co., Ltd. to advance the research and development of probiotic drugs [1] - The company has accumulated a wealth of strain resources and key processes in core technologies, and its project on "Key Technology Creation and Application for the Excavation and Industrialization of Excellent Lactic Acid Bacteria Germplasm Resources" won the second prize of the 2023 National Science and Technology Progress Award [1]

Group 1 - The company, Kato Biotech, is actively advancing the research and development of probiotic new drug projects in collaboration with Shenzhen Unknown Jun Biotechnology Co., Ltd. and other pharmaceutical enterprises [1] - The company will provide timely information disclosure based on the progress of these projects [1]

Group 1 - The company is actively advancing its research and development of probiotic new drug projects in collaboration with Shenzhen Unknown Jun Biotechnology Co., Ltd. and other pharmaceutical enterprises [2] - The company will provide timely information disclosure based on the progress of these projects [2]

Group 1 - The company operates in the food manufacturing industry, focusing on the research, production, and sales of probiotic products, plant and animal micro-ecological preparations, and compound food additives [2] - The company has also made initial investments in the pharmaceutical sector, collaborating with Shenzhen Unknown Jun Biotechnology Co., Ltd. to advance the research and development of probiotic drugs [2] - The company has accumulated a rich resource of strains and key processes, and its project on "Key Technology Creation and Application for the Excavation and Industrialization of Excellent Lactic Acid Bacteria Germplasm Resources" won the second prize of the 2023 National Science and Technology Progress Award [2]